Last $3.27 USD
Change Today +0.12 / 3.81%
Volume 3.1M
GERN On Other Exchanges
As of 8:10 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

geron corp (GERN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/24/14 - $5.59
52 Week Low
03/12/14 - $1.31
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GERON CORP (GERN)

geron corp (GERN) Related Businessweek News

No Related Businessweek News Found

geron corp (GERN) Details

Geron Corporation, a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

46 Employees
Last Reported Date: 03/17/14
Founded in 1990

geron corp (GERN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $569.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Executive Vice President of Development and T...
Total Annual Compensation: $367.4K
Executive Vice President of Legal Affairs & H...
Total Annual Compensation: $302.2K
Executive Vice President of Business Developm...
Total Annual Compensation: $341.6K
Compensation as of Fiscal Year 2013.

geron corp (GERN) Key Developments

Geron Corporation - Shareholder/Analyst Call

To present a company overview and discuss data presented at the 56th American Society of Hematology (ASH) Annual Meeting; and to discuss preclinical proof-of-concept data on imetelstat in acute myelogenous leukemia which was published in Cell Stem Cell as well as presented at the 56th ASH Annual Meeting

Geron Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 04:00 PM

Geron Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 04:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: John A. Scarlett, Chief Executive Officer, President and Director.

Geron Corporation Enters into License Agreement with Janssen Biotech to Develop Cancer Drug

Geron Corporation has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech Inc. to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Under the terms of the agreement, Geron will receive an initial payment of $35 million due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:US $3.27 USD +0.12

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.44 USD -0.0301
BioTime Inc $3.46 USD -0.03
IntelliCell BioSciences Inc $0.0001 USD 0.00
Neuralstem Inc $2.64 USD -0.06
ReNeuron Group PLC 3.38 GBp -0.125
View Industry Companies

Industry Analysis


Industry Average

Valuation GERN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 411.7x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 307.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at